Innovations In Clinical Neuroscience

SEP-OCT 2014

A peer-reviewed, evidence-based journal for clinicians in the field of neuroscience

Issue link: http://innovationscns.epubxp.com/i/425963

Contents of this Issue

Navigation

Page 38 of 201

[ V O L U M E 1 1 , N U M B E R 9 – 1 0 , S E P T E M B E R – O C T O B E R 2 0 1 4 ] Innovations in CLINICAL NEUROSCIENCE 39 T ABLE 4. Percent agreement, n ( %), kappa, and AUC for ISST- Plus vs. C-SSRS and S-STS v s. C-SSRS ISST-PLUS ( N = 40) S-STS (PATIENT) ( N = 40) S-STS (CLINICIAN) ( N = 40) S-STS (RECONCILED) ( N = 39) N o Y es N o Y es N o Y es N o Y es FDA-CASA 2012 Category 1: Passive suicidal ideation C -SSRS No Y es 4 (10.0) 1 (2.5) 0 3 5 (87.5) 3 (7.5) 1 (2.5) 1 (2.5) 3 5 (87.5) 3 (7.5) 2 (5.0) 1 (2.5) 3 4 (85.0) 3 (7.7) 2 (5.1) 1 (2.6) 33 (84.6) % agreement* P value** K appa (95% CL) A UC 39/40 (97.5) 0.317 0 .875 (0.635, 1.000) 0 .986 38/40 (95.0) 1.000 0 .722 (0.357, 1.000) 0 .861 37/40 (92.5) 0.564 0 .625 (0.237, 1.000) 0 .847 36/39 (92.3) 0.564 0 .624 (0.235, 1.000) 0 .846 FDA-CASA 2012 Category 2: Active suicidal ideation: nonspecific C-SSRS No Yes 10 (25.0) 26 (65.0) 2 (5.0) 2 (5.0) 12 (30.0) 28 (70.0) 0 0 10 (25.0) 28 (70.0) 2 (5.0) 0 11 (28.2) 27 (69.2) 1 (2.6) 0 % Agreement* P value** Kappa (95% CL) AUC 1 2/40 (30.0) < 0.001 -0.061 (-0.212, 0.090) 0.452 1 2/40 (30.0) - - 0.500 1 0/40 (25.0) < 0.001 -0.103 (-0.246, 0.040) 0.417 1 1/39 (28.2) < 0.001 -0.052 (-0.154, 0.050) 0.458 FDA-CASA 2012 Category 3: Active suicidal ideation: method, but no intent or plan C-SSRS No Yes 12 (30.0) 23 (57.5) 1 (2.5) 4 (10.0) 13 (32.5) 27 (67.5) 0 0 13 (32.5) 25 (62.5) 0 2 (5.0) 13 (33.3) 24 (61.5) 0 2 (5.1) % Agreement* P value** Kappa (95% CL) A UC 1 6/40 (40.0) <0.001 0.071 (-0.090, 0.189) 0 .536 1 3/40 (32.5) - - 0 .500 1 5/40 (37.5) <0.001 0.049 (-0.021, 0.120) 0 .537 1 5/39 (38.5) <0.001 0.053 (-0.023, 0.128) 0 .538 FDA-CASA 2012 Category 4: Active suicidal ideation: method and intent, but no plan C-SSRS No Yes 17 (42.5) 22 (55.0) 1 (2.5) 0 18 (45.0) 20 (50.0) 0 2 (5.0) 17 (42.5) 20 (50.0) 1 (2.5) 2 (5.0) 17 (43.6) 20 (51.3) 1 (2.6) 1 (2.6) % Agreement* P value** Kappa (95% CL) AUC 17/40 (42.5) <0.001 -0.050 (-0.148, 0.047) 0.472 20/40 (50.0) <0.001 0.083 (-0.003, 0.196) 0.545 19/40 (47.5) <0.001 0.032 (-0.114, 0.179) 0.518 18/39 (46.2) <0.001 -0.007 (-0.137, 0.122) 0.496 FDA-CASA 2012 Category 5: Active suicidal ideation: method, intent, and plan C-SSRS No Yes 20 (50.0) 5 (12.5) 3 (7.5) 12 (30.0) 16 (40.0) 0 7 (17.5) 17 (42.5) 19 (47.5) 3 (7.5) 4 (10.0) 14 (35.0) 18 (46.2) 1 (2.6) 5 (12.8) 15 (38.5) % Agreement* P value** Kappa (95% CL) AUC 32/40 (80.0) 0.480 0.584 (0.329, 0.840) 0.788 33/40 (82.5) 0.008 0.660 (0.445, 0.875) 0.848 33/40 (82.5) 0.705 0.645 (0.406, 0.883) 0.825 33/39 (84.6) 0.102 0.694 (0.473, 0.914) 0.860 FDA-CASA 2012 Category 7: Suicidal attempt C-SSRS No Yes 30 (75.0) 2 (5.0) 0 8 (20.0) 30 (75.0) 2 (5.0) 0 8 (20.0) 30 (75.0) 3 (7.5) 0 7 (17.5) 29 (74.4) 2 (5.1) 0 8 (20.5) % Agreement* P value** Kappa (95% CL) AUC 38/40 (95.0) 0.157 0.857 (0.666, 1.000) 0.900 38/40 (95.0) 0.157 0.857 (0.666, 1.000) 0.900 37/40 (92.5) 0.083 0.778 (0.542, 1.000) 0.850 37/39 (94.9) 0.157 0.856 (0.664, 1.000) 0.900 FDA-CASA 2012 Category 8: Interrupted suicide attempt C-SSRS No Yes 32 (80.0) 8 (20.0) 0 0 32 (80.0) 5 (12.5) 0 3 (7.5) 31 (77.5) 6 (15.0) 1 (2.5) 2 (5.0) 31 (79.5) 8 (20.5) 0 0 % Agreement* P value** Kappa (95% CL) AUC 32/40 (80.0) - - 0.500 35/40 (87.5) 0.025 0.490 (0.130, 0.850) 0.688 33/40 (82.5) 0.059 0.286 (-0.082, 0.653) 0.609 31/39 (79.5) - - 0.500 FDA-CASA 2012 Category 9: Aborted suicide attempt C-SSRS No Yes 36 (90.0) 4 (10.0) 0 0 36 (90.0) 3 (7.5) 0 1 (2.5) 35 (87.5) 3 (7.5) 1 (2.5) 1 (2.5) 35 (89.7) 4 (10.3) 0 0 % Agreement* P value** Kappa (95% CL) AUC 36/40 (90.0) - - 0.500 37/40 (92.5) 0.083 0.375 (-0.156, 0.906) 0.625 36/40 (90.0) 0.317 0.286 (-0.214, 0.786) 0.611 35/39 (89.7) - - 0.500

Articles in this issue

Archives of this issue

view archives of Innovations In Clinical Neuroscience - SEP-OCT 2014